B-cell acute lymphoblastic leukemia · 7 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Nilotinib monotherapy Variant #01 | BCR::ABL1 | R 28 002 | 28d | — | — | ~2 | ~R 56 004 indirect | — |
Dasatinib, Vincristine, Prednisone Variant #01 | BCR::ABL1 | R 13 102 | 28d | — | — | ~26 | ~R 340 640 indirect | — |
Dasatinib monotherapy Variant #01 | BCR::ABL1 | R 12 899 | 28d | — | — | ~2 | ~R 25 797 indirect | — |
POMP Variant #01 | — | R 9 449 | 30d | — | — | ~24 | ~R 226 776 indirect | — |
Imatinib, Vincristine, Prednisone Variant #01 | BCR::ABL1 | R 8 607 | 28d | — | — | ~11 | ~R 94 678 indirect | — |
Mercaptopurine, Methotrexate, Vincristine, Dexamethasone N/A - intrathecal component | — | R 6 907 | 84d | — | — | ~8 | ~R 55 256 indirect | — |
Mercaptopurine and Methotrexate Variant #05 | — | R 2 185 | 14d | — | — | ~26 | ~R 56 797 indirect | — |
7 of 7 regimens shown